$10.68 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Tricida

Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts in the gastrointestinal tract and clears the human body through the digestive system, by preventing degradation and systemic uptake.

Stock Analysis

last close $10.68
1-mo return 13.7%
3-mo return 11.6%
avg daily vol. 739.39T
52-week high 12.45
52-week low 3.55
market cap. $534M
forward pe -
annual div. -
roe -324%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 95.1%

Subscribe now for daily local and international financial news